Analysis Proposal
Analysis Question
Can we validate the physical or functional interaction between OCLN and CLDN5 in neurodegenerative disease contexts?
Datasets
STRINGdb v11.5 (protein-protein interaction network, score threshold >0.4)BrainSpan RNA-seq developmental atlas (tissue-specific expression)Accelerating Medicines Partnership - Alzheimer's Disease (AMP-AD) gene expression cohorts
Methods
STRING database lookup for direct physical interaction evidence (experimental + computational)Pearson correlation analysis of OCLN/CLDN5 co-expression in human brain tissue samplesGene set enrichment analysis (GSEA) for tight junction / blood-brain barrier pathways in AD cohortsText mining of PubMed abstracts using named entity recognition for co-occurrence validation
Expected Outputs
- STRING combined score >0.7 indicating validated physical interaction between OCLN and CLDN5
- Significant positive Pearson correlation (r>0.5, p<0.05) between OCLN and CLDN5 expression in AD-affected brain regions
- Enrichment of OCLN/CLDN5 in blood-brain barrier dysfunction gene modules associated with AD severity
- Literature evidence of >5 independent publications reporting co-mention of both genes in neurodegeneration contexts